Douglas A. Levine, MD | Authors

Articles

Efficacy of Niraparib on PFS in Patients With Recurrent Ovarian Cancer

September 25, 2017

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, and director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the efficacy of niraparib (Zejula) on progression-free survival in patients with recurrent ovarian cancer with partial response to the last platinum-based chemotherapy.

The Complexity of the PARP Inhibitor Landscape in Ovarian Cancer

June 16, 2017

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, and director, Divison of Gynecologic Oncology, NYU Langone Medical Center, discusses the impact of PARP inhibitors on the landscape of ovarian cancer.

Current Challenges in the Ovarian Cancer Field

February 17, 2017

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses challenges currently facing the ovarian cancer field.